Few data are available about the concomitant detection of MET gene amplification and exon 14 skipping, however, concurrent MET amplification has been reported in 15–21% of MET exon 14 positive NSCLC, and METY1003X mutations account for around 2% of the MET exon 14 alterations in NSCL [23,24,25]. Here, MET is linked to non-small cell lung carcinoma.